Inhibikase Therapeutics, Inc.

The following table sets forth the aggregate fees billed by CohnReznick LLP in connection with audit and other services rendered during the past two fiscal years.

(1)

Audit fees in 2025 and 2024 include fees related to the annual audit of our financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and comfort letters, consents and assistance with and review of documents filed with the SEC.

(2)

There were no audit-related fees incurred in 2025 or 2024.

(3)

Tax fees are related to tax compliance, tax advice and tax planning services, including the review and preparation of our federal and state income tax returns.

(4)

There were no other fees incurred in 2025 or 2024.

The audit committee pre-approved all services described above in accordance with the pre-approval policies and procedures described below.

Audit Committee Pre-Approval Policies and Procedures

The audit committee is responsible for appointing, retaining, setting compensation for, and evaluating and overseeing the work of the independent registered public accounting firm. The audit committee’s charter establishes a policy that all audit and permissible non-audit services provided by the independent registered public accounting firm will be pre-approved by the audit committee.

All such audit and permissible non-audit services were pre-approved in accordance with this policy during the fiscal year ended December 31, 2025. These services may include audit services, audit-related services, tax services and other services. The audit committee considers whether the provision of each non-audit service is compatible with maintaining the independence of our independent registered public accounting firm. The responsibility to pre-approve audit and non-audit services may be delegated by the audit committee to one or more members of the audit committee; provided that any decisions made by such member or members must be presented to the full audit committee at its next scheduled meeting.

INDEX TO FINANCIAL STATEMENTS

Board of Directors and Stockholders of Inhibikase Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Inhibikase Therapeutics, Inc. and Subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Stock Based Compensation – Initial Measurement of Fair Value

As described further in Note 2 of the notes to the consolidated financial statements with regards to the policy note on Stock-Based Compensation, the Company issued certain options that were deemed complex option structures. To estimate the grant date fair value of the complex option structure awards, the Company utilized a Monte Carlo valuation model to estimate a range of potential future outcomes over the expected term of the awards. With the assistance of valuation specialists, the Company estimated the fair value of the complex option structures awarded during the year ended December 31, 2025.

We identified the assessment of the fair value of the complex option structure awards as a critical audit matter associated with the complexity of management's judgments and estimates related to the valuation of the complex option structure awards. Given these factors, the related audit effort in evaluating management's judgments and estimates in assessing the valuation of the complex option structure awards was complex, subjective and challenging and required a high degree of auditor judgment.

How our Audit Addressed the Critical Audit Matter

Our principal audit procedures related to this critical audit matter included the following:

•

We obtained an understanding of and evaluated the design and implementation of controls that addressed the risk of material misstatement for the valuation of the complex option structure awards.

•

We evaluated management's significant accounting policies related to valuation of option awards for reasonableness.

•

We assessed whether the use of a Monte Carlo simulation model was appropriate for the characteristics of the awards.

•

We inspected the grant agreements to understand the key terms and conditions that affect fair value.

•

We tested the reasonableness of the key assumptions used in the valuation, including stock price, volatility, risk free interest rates, exercise conditions and probability assessments.

•

We involved valuation professionals to evaluate the methodology, assumptions and results of the Monte Carlo valuation, including the final grant date fair value conclusion.

Asset Purchase Agreement – CorHepta Pharmaceuticals, Inc.

As described further in Note 7 in the consolidated financial statements, the Company entered into an Agreement and Plan of Merger and Reorganization with CorHepta Pharmaceuticals, Inc. (the "Acquisition Agreement"). The Acquisition Agreement included a contingent consideration provision subject to the achievement of certain milestones, which is required to be recognized at fair value, along with post-merger compensation expense subject to both service based and performance based vesting conditions.

The financial reporting of the Acquisition Agreement involved significant judgments and estimates by management in the determination of the accounting for the asset acquisition, accounting for the post-merger compensation expense and probability assessments related to the contingent consideration included in the terms of the Acquisition Agreement. Given these factors, the related audit effort in evaluating management's accounting and judgments of the Acquisition Agreement was complex, subjective and challenging and required a high degree of auditor judgment.

How our Audit Addressed the Critical Audit Matter

Our principal audit procedures related to this critical audit matter included the following:

•

We obtained an understanding of and evaluated the design and implementation of controls that addressed the risk of material misstatement for the financial reporting of the Acquisition Agreement.

•

We evaluated management's significant accounting policies related to asset acquisitions for reasonableness.

•

We inspected the Acquisition Agreement to understand the components of consideration, including contingent consideration and post-merger compensation expense.

•

We assessed the probability of certain milestones being met, including both service and performance conditions which impact the determination of the overall merger consideration, including contingent consideration and post-merger compensation expense.

•

We involved individuals with specialized skill and knowledge to assist in testing the Company's methodology and significant assumptions involved in the terms of the Acquisition Agreement.

•

We recalculated the remeasurement of the fair value of the contingent consideration as of the reporting date.

•

We evaluated the adequacy of the related consolidated financial statement disclosures.

/s/CohnReznick LLP

We have served as the Company's auditor since 2018.

Holmdel, New Jersey

March 26, 2026